{"DataElement":{"publicId":"3124352","version":"1","preferredName":"Leukemia French American British Morphology Code","preferredDefinition":"Alphanumeric code to represent the French American British (FAB) morphologic classification of leukemia.","longName":"3124331v1.0:3124340v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3124331","version":"1","preferredName":"Leukemia French American British Morphology Classification","preferredDefinition":"related to the grouping of hematologic malignancy (e.g., leukemia) based on criteria for morphologic and cytochemical appearance describe by the French-American-British international system._The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope._A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","longName":"2456829v1.0:3144329v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2456829","version":"1","preferredName":"Leukemia","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","longName":"C3161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E070B71-9210-1732-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-13","modifiedBy":"ONEDATA","dateModified":"2006-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3144329","version":"1","preferredName":"Morphology French-American-British Classification Classification","preferredDefinition":"Morphology is the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.:A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes. It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"C17943:C91220:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphology","conceptCode":"C17943","definition":"The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"French-American-British Classification","conceptCode":"C91220","definition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"917B0EF2-7FAC-0B84-E040-BB89AD43388A","latestVersionIndicator":"Yes","beginDate":"2010-09-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-30","modifiedBy":"ONEDATA","dateModified":"2010-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C1373DE-778D-5CA2-E040-BB89AD436AB3","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3124340","version":"1","preferredName":"Leukemia Morphology Code","preferredDefinition":"Text code terms to represent the marrow diagnostic category for a patient with acute leukemia._The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","longName":"3124340v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Biphenotypic","valueDescription":"Acute biphenotypic leukaemia is a form of leukaemia where the lineage is of both lymphoid and myeloid origin; It is a subtype of ","ValueMeaning":{"publicId":"3124341","version":"1","preferredName":"Acute biphenotypic leukaemia is a form of leukaemia where the lineage is of both lymphoid and myeloid origin; It is a subtype of ","longName":"3124341","preferredDefinition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Biphenotypic Leukemia","conceptCode":"C4673","definition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3911-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-392A-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M0 Undifferentiated","valueDescription":"Minimally differentiated acute myeloblastic leukemia","ValueMeaning":{"publicId":"3124342","version":"1","preferredName":"Minimally differentiated acute myeloblastic leukemia","longName":"3124342","preferredDefinition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.  The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies.  The patients present with anemia, neutropenia, and thrombocytopenia.  The prognosis is usually poor.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Minimal Differentiation","conceptCode":"C8460","definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3934-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-394D-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M6","valueDescription":"Acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)","ValueMeaning":{"publicId":"3124343","version":"1","preferredName":"Acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)","longName":"3124343","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia.  Severe anemia is a common symptom.  This leukemia usually follows an aggressive clinical course.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3957-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3970-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M5","valueDescription":"Acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b)","ValueMeaning":{"publicId":"3124344","version":"1","preferredName":"Acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b)","longName":"3124344","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features. It usually follows an aggressive clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-397A-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3993-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M4EOS","valueDescription":"Myelomonocytic together with bone marrow eosinophilia","ValueMeaning":{"publicId":"3124345","version":"1","preferredName":"Myelomonocytic together with bone marrow eosinophilia","longName":"3124345v1.00","preferredDefinition":"Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia with Abnormal Eosinophils","conceptCode":"C9020","definition":"Acute myelomonocytic leukemia characterized by the presence of abnormal bone marrow eosinophils. It is associated with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22). It has a favorable prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-399D-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-39B6-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M3","valueDescription":"Promyelocytic, or acute promyelocytic leukemia (APL)","ValueMeaning":{"publicId":"3124346","version":"1","preferredName":"Promyelocytic, or acute promyelocytic leukemia (APL)","longName":"3124346","preferredDefinition":"Acute Promyelocytic leukemia characterized by the presence of hypergranular promyelocytes and characteristic cells that contain bundles of Auer rods.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Typical Acute Promyelocytic Leukemia","conceptCode":"C27756","definition":"Acute Promyelocytic leukemia characterized by the presence of hypergranular promyelocytes and characteristic cells that contain bundles of Auer rods.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-39C0-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-39D9-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M2","valueDescription":"Acute myeloblastic leukemia, with granulocytic maturation","ValueMeaning":{"publicId":"3124347","version":"1","preferredName":"Acute myeloblastic leukemia, with granulocytic maturation","longName":"3124347","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. Patients often present with anemia, neutropenia, and thrombocytopenia. AML with the t(8;21) is usually AML with maturation. This type of AML frequently responds to aggressive therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-39E3-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-39FC-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M1","valueDescription":"Acute myeloblastic leukemia, without maturation","ValueMeaning":{"publicId":"3124348","version":"1","preferredName":"Acute myeloblastic leukemia, without maturation","longName":"3124348","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils.  The patients present with anemia, neutropenia, and thrombocytopenia.  This type of AML usually follows an aggressive clinical course.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3A06-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A1F-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"Not classified","valueDescription":"Not classified","ValueMeaning":{"publicId":"3124349","version":"1","preferredName":"Not classified","longName":"3124349","preferredDefinition":"Not arranged or included in any specific grouping.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unclassified","conceptCode":"C64486","definition":"Not arranged or included in any specific grouping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3A29-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A42-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"Unchanged","valueDescription":"No Change","ValueMeaning":{"publicId":"2570474","version":"1","preferredName":"No Change","longName":"2570474","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: The act of alteration or modification; changed or altered in form or character.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Change","conceptCode":"C25446","definition":"The act of alteration or modification; changed or altered in form or character.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E057-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"LUY","dateModified":"2015-02-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A56-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Not known or not well known","ValueMeaning":{"publicId":"3124350","version":"1","preferredName":"Not known or not well known","longName":"3124350","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-3A61-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A7A-8731-E040-BB89AD437683","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M4","valueDescription":"Acute myelomonocytic leukemia (AMML)","ValueMeaning":{"publicId":"2578415","version":"1","preferredName":"Acute myelomonocytic leukemia (AMML)","longName":"2578415","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils.  The patients present with anemia, neutropenia, and thrombocytopenia.  This type of AML usually follows an aggressive clinical course.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-29","modifiedBy":"LUY","dateModified":"2015-02-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A84-8731-E040-BB89AD437683","beginDate":"2006-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M7","valueDescription":"Acute megakaryocytic leukemia","ValueMeaning":{"publicId":"2578418","version":"1","preferredName":"Acute megakaryocytic leukemia","longName":"2578418","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage.  The prognosis is usually poor.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF5F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-29","modifiedBy":"LUY","dateModified":"2015-02-03","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C142120-3A8E-8731-E040-BB89AD437683","beginDate":"2006-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","deletedIndicator":"No"},{"value":"M3v","valueDescription":"Microgranular Acute Promyelocytic Leukemia","ValueMeaning":{"publicId":"3165501","version":"1","preferredName":"Microgranular Acute Promyelocytic Leukemia","longName":"3165501v1.00","preferredDefinition":"Acute promyelocytic leukemia in which the promyelocytes in the peripheral blood have paucity or absence of cytoplasmic granules and characteristic bilobed nuclei.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microgranular Acute Promyelocytic Leukemia","conceptCode":"C27757","definition":"Acute promyelocytic leukemia in which the promyelocytes in the peripheral blood have paucity or absence of cytoplasmic granules and characteristic bilobed nuclei.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96EC6B62-CDA9-7D7A-E040-BB89AD436C04","latestVersionIndicator":"Yes","beginDate":"2010-12-08","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-08","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"FAB Classification","id":"96EC6B62-CDC2-7D7A-E040-BB89AD436C04","beginDate":"2010-12-08","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-08","modifiedBy":"ONEDATA","dateModified":"2010-12-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3124339","version":"1","preferredName":"Morphology Code","preferredDefinition":"Morphology is the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.:A system of numbered categories for representation of data.","longName":"C17943:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphology","conceptCode":"C17943","definition":"The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-38EB-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"ONEDATA","dateModified":"2010-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C142120-38FC-8731-E040-BB89AD437683","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":"2023.8.28 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787505","version":"1","longName":"HNSC","context":"NCIP"},{"publicId":"3787508","version":"1","longName":"KIRP","context":"NCIP"},{"publicId":"3787513","version":"1","longName":"LUSC","context":"NCIP"},{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"},{"publicId":"3787502","version":"1","longName":"CESC","context":"NCIP"},{"publicId":"3787503","version":"1","longName":"COAD","context":"NCIP"},{"publicId":"3787506","version":"1","longName":"KICH","context":"NCIP"},{"publicId":"3787507","version":"1","longName":"KIRC","context":"NCIP"},{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"},{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"},{"publicId":"3787510","version":"1","longName":"LGG","context":"NCIP"},{"publicId":"3787509","version":"1","longName":"LAML","context":"NCIP"},{"publicId":"3787511","version":"1","longName":"LIHC","context":"NCIP"},{"publicId":"3787519","version":"1","longName":"SKCM","context":"NCIP"},{"publicId":"3787512","version":"1","longName":"LUAD","context":"NCIP"},{"publicId":"3787517","version":"1","longName":"READ","context":"NCIP"},{"publicId":"3787518","version":"1","longName":"SARC","context":"NCIP"},{"publicId":"3787520","version":"1","longName":"STAD","context":"NCIP"},{"publicId":"3787522","version":"1","longName":"UCEC","context":"NCIP"},{"publicId":"3787521","version":"1","longName":"THCA","context":"NCIP"},{"publicId":"3787515","version":"1","longName":"PAAD","context":"NCIP"}]},{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650572","version":"1","longName":"AML","context":"OCG"}]}],"AlternateNames":[{"name":"fab_category","type":"TCGA_XML_Name","context":"NCIP"},{"name":"leukemia_french_american_british_morphology_code","type":"TCGA_XML_Name","context":"NCIP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"FAB Category","type":"Preferred Question Text","description":"FAB Category","url":null,"context":"NCIP"},{"name":"French American British AML Classification","type":"Alternate Question Text","description":"French American British AML Classification","url":null,"context":"NCIP"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Primary morphology of the patient's AML","url":null,"context":"COG"}],"origin":"FAB Classification","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C14A4CF-1A71-B224-E040-BB89AD432422","latestVersionIndicator":"Yes","beginDate":"2010-07-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-07-23","modifiedBy":"TSESU","dateModified":"2018-07-11","changeDescription":"Released per approval from T.Davidsen. mc 4/18/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}